Indoco Remedies Ltd

Indoco Remedies Ltd

₹ 328 0.37%
24 Jun - close price
About

Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]

Key Points

Business segments
A) Domestic Formulations (41% of FY22 revenue)[1] Company offers high-quality medicines in multiple therapeutic categories, which include diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicines.
The Company has a predominant presence in the South (37%) and West (33%), followed by the East (17%) and North (12%). The Company caters to multiple doctor specialties and generates more than 83 million prescriptions annually from over 3,00,000 doctors across India

  • Market Cap 3,026 Cr.
  • Current Price 328
  • High / Low 417 / 286
  • Stock P/E 28.0
  • Book Value 122
  • Dividend Yield 0.69 %
  • ROCE 11.9 %
  • ROE 10.0 %
  • Face Value 2.00

Pros

Cons

  • Dividend payout has been low at 13.3% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
305 386 387 358 409 408 433 399 427 423 473 449 445
250 300 300 284 328 337 345 337 363 360 401 384 388
Operating Profit 55 87 86 73 80 71 88 62 64 63 72 65 57
OPM % 18% 22% 22% 21% 20% 17% 20% 15% 15% 15% 15% 15% 13%
2 1 1 0 0 1 0 0 0 0 1 -5 24
Interest 5 4 3 4 3 4 5 7 9 8 8 10 11
Depreciation 19 22 19 19 18 20 16 17 18 20 21 23 24
Profit before tax 33 61 65 51 60 48 67 38 38 36 44 27 46
Tax % 26% 35% 36% 35% 32% 20% 26% 26% 34% 27% 25% 26% 19%
25 40 42 33 40 38 50 28 25 26 33 20 38
EPS in Rs 2.70 4.30 4.51 3.58 4.38 4.17 5.39 3.02 2.75 2.81 3.60 2.17 4.07
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
629 726 851 1,005 1,072 1,038 968 1,106 1,240 1,540 1,667 1,791
536 606 686 834 915 903 891 982 1,016 1,212 1,380 1,533
Operating Profit 93 120 165 171 157 135 77 124 224 328 286 258
OPM % 15% 17% 19% 17% 15% 13% 8% 11% 18% 21% 17% 14%
1 2 2 1 4 5 6 2 3 2 1 20
Interest 22 19 10 12 6 24 21 26 22 14 25 37
Depreciation 24 31 47 61 63 68 72 71 73 79 71 88
Profit before tax 48 72 109 99 91 48 -9 29 131 236 192 153
Tax % 12% 20% 24% 17% 15% 15% 69% 16% 30% 35% 26% 24%
43 58 83 82 77 41 -3 24 92 155 141 117
EPS in Rs 4.63 6.28 8.99 8.93 8.41 4.47 -0.31 2.63 10.03 16.77 15.34 12.65
Dividend Payout % 24% 22% 18% 18% 19% 22% -97% 11% 15% 13% 15% 12%
Compounded Sales Growth
10 Years: 9%
5 Years: 13%
3 Years: 13%
TTM: 7%
Compounded Profit Growth
10 Years: 6%
5 Years: 112%
3 Years: 5%
TTM: -24%
Stock Price CAGR
10 Years: 7%
5 Years: 16%
3 Years: -6%
1 Year: 0%
Return on Equity
10 Years: 11%
5 Years: 12%
3 Years: 14%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 18 18 18 18 18 18 18 18 18 18 18 18
Reserves 396 439 500 558 633 657 643 662 750 886 1,009 1,108
118 91 94 139 280 282 296 262 267 257 333 514
157 178 229 224 266 280 301 330 281 327 300 320
Total Liabilities 689 726 842 939 1,197 1,238 1,258 1,272 1,317 1,488 1,660 1,961
321 325 339 373 440 489 468 590 570 555 661 754
CWIP 38 44 63 55 91 136 185 51 68 122 113 92
Investments 0 0 1 18 3 3 2 2 2 2 20 59
330 356 439 493 664 611 603 630 676 809 866 1,055
Total Assets 689 726 842 939 1,197 1,238 1,258 1,272 1,317 1,488 1,660 1,961

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
69 100 110 112 88 123 132 123 82 174 176 177
-43 -41 -88 -113 -171 -135 -104 -56 -67 -121 -205 -302
-26 -58 -21 0 132 -39 -16 -64 -30 -44 23 122
Net Cash Flow -0 1 1 -0 50 -51 12 3 -14 8 -7 -3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 74 69 66 68 73 73 73 69 69 70 77 83
Inventory Days 129 147 179 173 188 204 209 230 245 248 228 207
Days Payable 95 94 145 137 167 158 195 184 119 108 89 79
Cash Conversion Cycle 108 122 100 103 95 119 88 115 195 210 217 211
Working Capital Days 74 73 77 79 80 77 64 56 107 113 118 126
ROCE % 14% 17% 21% 17% 12% 7% 1% 6% 16% 23% 17%

Shareholding Pattern

Numbers in percentages

10 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
58.69% 58.69% 58.69% 58.69% 58.69% 58.68% 58.68% 58.69% 58.73% 58.75% 58.75% 58.72%
2.29% 2.43% 1.62% 1.15% 1.17% 1.19% 1.23% 1.55% 1.58% 1.59% 1.69% 1.92%
19.28% 17.69% 17.78% 18.27% 18.07% 17.97% 18.07% 18.06% 17.93% 17.79% 19.56% 19.41%
19.74% 21.19% 21.91% 21.89% 22.07% 22.16% 22.00% 21.69% 21.75% 21.87% 20.00% 19.92%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03%
No. of Shareholders 24,51834,74637,27937,86338,49838,07235,71334,73135,43136,58832,60033,201

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls